The JAK3 Knockout Ca Ski Polyclonal Cells product comprises a heterogeneous population of Ca Ski human cervical carcinoma cells engineered via CRISPR/Cas9-mediated gene disruption to ablate functional expression of the JAK3 gene. This polyclonal knockout model provides a powerful tool for investigating JAK3-dependent signaling networks and their contribution to cervical cancer phenotypes, enabling bulk-level studies without clonal selection bias.
The parental Ca Ski cell line is an epithelial model established from a cervical epidermoid carcinoma metastasis, characterized by stable integration of the human papillomavirus type 16 (HPV-16) genome. These adherent cells retain key features of cervical cancer pathophysiology, including dysregulated cell cycle control and oncogenic signaling, making them a relevant host for dissecting the molecular determinants of HPV-driven tumorigenesis.
JAK3 encodes a non-receptor tyrosine kinase that serves as a critical signaling node downstream of common gamma chain (??c)-containing cytokine receptors, including those for IL-2, IL-7, IL-9, IL-15, and IL-21. Upon cytokine stimulation, JAK3 is recruited to the receptor complex and mediates tyrosine phosphorylation of STAT5 and STAT3, which dimerize and enter the nucleus to transcriptionally regulate target genes such as c-Myc, Bcl-xL, and Cyclin D1. In addition to the JAK-STAT axis, JAK3 contributes to the activation of the PI3K/AKT and MAPK/ERK cascades, integrating signals that govern proliferation, survival, and differentiation. Key interacting partners that modulate its activity include the adaptor SH2B1 and the suppressor SOCS1, forming a tightly regulated signaling microenvironment.
In the context of HPV-positive cervical carcinoma, JAK3 signaling may contribute to malignant phenotypes by enhancing cell proliferation and resistance to apoptosis, potentially co-operating with HPV oncoproteins to sustain tumor growth. The JAK3 Knockout Ca Ski Polyclonal Cells thus offer a physiologically relevant platform to parse the specific contributions of cytokine receptor signaling to epithelial tumor cell fitness, independent of the well-characterized hematopoietic roles of JAK3. Disruption of JAK3 in these cells is expected to attenuate downstream effectors such as phospho-STAT5 and phospho-AKT, enabling direct functional interrogation of JAK3 as a driver of cervical cancer progression.
Researchers can employ this knockout model in a variety of functional studies, including western blot analysis of phospho-STAT5 and phospho-AKT to monitor signal attenuation, RT?qPCR quantification of c-Myc and Bcl-xL, and cell viability or apoptosis assays to gauge JAK3-dependent survival signals. The polyclonal population is also amenable to colony formation and migration/invasion assays, as well as cytokine stimulation with IL-2 or IL-7 to delineate pathway activation. Furthermore, these cells enable drug sensitivity profiling of JAK inhibitors, facilitating preclinical evaluation of therapeutic strategies against cervical cancer. For further information, please contact Ascent Research.
